Neoadjuvant Treatment for Pancreatic Adenocarcinoma CH MAN Department of Surgery Caritas Medical Centre.

Slides:



Advertisements
Similar presentations
Neoadjuvant therapy for Rectal cancer
Advertisements

IN THE NAME OF GOD. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy The American Journal.
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Radiation Therapy for Pancreatic Cancers Eyad Abu-Isa, M.D. Assistant Professor, Radiation Oncology University of Michigan/Providence Cancer Institute.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
Great Debates & Updates in GI Malignancies
Management of Pancreato- biliary Malignancy: Medical Oncology Perspective Robert A. Wolff, MD Professor of Medicine Department of GI Medical Oncology.
Borderline Resectable Pancreatic Carcinoma
 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
Incorporating Cesium-131 Interstitial Implants into Daily Clinical Practice: How to Make Radiation appear exactly where you want. Jonathan Feddock, MD.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Pancreatic cancer: What defines resectability and the role for surgery
DEBATE: What is the Optimal Strategy for Liver Only Metastatic Colon Cancer? Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Management of Colorectal Liver Metastasis
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
DOWNSTAGING LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA (LAPC) WITH VASCULAR ENCASEMENT USING PERCUTANEOUS IRREVERSIBLE ELECTROPORATION (IRE) NARAYANAN,GOVINDARAJAN;
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
GIC Protocol Meeting Ca Stomach Presentor-Dr Richa Madhawi Moderator- Dr S. Pathy.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We?
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC
Jennifer Borja Raiza Bondoc
Saint Agnes Medical Center Oncology Symposium October 15, 2011 Neoadjuvant, Adjuvant and Palliative Management Marshall Flam, MD Hematology, Oncology Medical.
Laparoscopic Pancreatectomy Attila Nakeeb, M.D., F.A.C.S. Department of Surgery Indiana University School of Medicine 7th Annual Symposium on Gastrointestinal.
The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Pancreatic Cancer. Pancreatic Cancer Case Case presentation 67 year old male Unremarkable previous medical history No family history of pancreatic cancer.
Pancreatic cancer.
Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Extra-Abdominal Fibromatosis : The Birmingham Experience
J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.
Therapeutic Delay and Survival after Surgery for Cancer of the Pancreatic Head with or without Preoperative Biliary Drainage Eshuis, van der Gaag, Rauws.
Pre-Operative Therapy for Borderline Resectable Pancreatic Cancer: The Potential Role of Chemotherapy Robert A. Wolff, M.D. Associate Professor of Medicine.
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma JIN Chen, YAO Lie, LONG.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.
Alliance A021101: Preoperative mFOLFIRINOX + Chemoradiation in Borderline Resectable Pancreatic Cancer CCO Independent Conference Highlights of the 2015.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.
Short-term outcome of neo-adjuvant chemotherapy
Surgical Management of the Breast in Breast Cancer
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
Borderline Resectable Pancreatic Cancer
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
Alice C. Wei, MDCM, MSc, FRCSC, FACS
Staging of Pancreatic Adenocarcinoma by Imaging Studies
Adjuvant Radiation is Required for Gastric Cancer
Neoadjuvant Adjuvant Curative Palliative
Role for XRT in treatment of early stage Follicular lymphoma?
Presentation transcript:

Neoadjuvant Treatment for Pancreatic Adenocarcinoma CH MAN Department of Surgery Caritas Medical Centre

Background Aggressive malignancy Overall median survival: 5-6 months 5-year survival rate: approx. 5% Risk factors: Smoking Heavy alcohol consumption Chronic pancreatitis Family history

Background (cont’d)

History of Pancreatic AdenoCa Treatment The only chance of cure: SURGICAL RESECTION Outcome not satisfactory Median survival: months 5-year survival after resection: less than 20% Recurrence in 30-50% of patients after presumed curative resection J Gastrointest Surg Mar-Apr;5(2): Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL.

History of Pancreatic AdenoCa Treatment (cont’d) In 1985, Gastrointestinal Tumor Study Group reported: Median survival of patients after resection prolonged for almost twofold by adjuvant chemoradiation 2-year survival: 42% in adjuvant chemoradiation group VS 15% in control group Arch Surg Aug;120(8): Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Kalser MH, Ellenberg SS.

RCT in 2008 Treatment with gemcitabine for 6 months after complete resection Significantly increases 5 years disease-free survival: 16% Median overall survival: 22.8 months J Clin Oncol26: 2008 Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotheraoy with gemcitabine versus observation in patients with resected pancreatic cancer. Neuhaus P, Riess H, etal. History of Pancreatic AdenoCa Treatment (cont’d)

Questions How to enhance the chance of resection? How to further improve the survival after resection besides adjuvant therapy?

Therapies Neoadjuvant Chemotherapy and Radiotherapy Is there a role? Who will benefit? What is the optimal regimen?

Pancreatic AdenoCa Resectable Absence of extrapancreatic disease Clear tissue plane around celiac axis, hepatic artery and SMA A patent SMV-PV confluence

Pancreatic AdenoCa Borderline resectable Absence of extrapancreatic disease Tumor involvement or occlusion of SMV/PV confluence amenable to resection and reconstruction Short segment of abutment/encasement of hepatic artery Tumor abutment of the SMA < 180 degrees of the circumference of the vessel

Pancreatic AdenoCa Unresectable Distant metastases Lymph nodes metastases beyond the field of resection Aortic invasion Greater than 180 degrees SMA encasement Unreconstructible SMV/portal occlusion

Potential Benefit of Neoadjuvant Therapy in Resectable Disease The administration is not affected by the surgical morbidities 20% of patients did not receive the assigned adjuvant therapy Occult metastases is allowed to manifest exclude patient from resection avoid the surgical morbidity Improve the chance of negative resection margin Ann Surg 1999; 230:776–82. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.

Neoadjuvant Therapy in Resectable Disease Involved resection margins are a poor prognostic factor

Neoadjuvant Therapy in Resectable Disease Negative impact on survival with an increasing number of positive margins J Gastrointest Surg Mar-Apr;5(2): Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL.

Neoadjuvant Therapy in Resectable Disease Neoadjuvant therapy can improve the chance of R0 resection and decrease the number of multiple positive margins J Gastrointest Surg Mar-Apr;5(2): Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL.

Neoadjuvant Therapy in Resectable Disease The overall median survival from the time of tissue diagnosis was 21 months At median 14 weeks of follow-up, 31% of patients showed no evidence of disease Survival duration is improved by the combination of neoadjuvant therapy and surgery

Neoadjuvant Therapy in Resectable Disease Phase II trial for preoperative gemcitabine-based chemoradiation and surgical treatment

Neoadjuvant Therapy in Resectable Disease Median survival was 34 months for patients who underwent neoadjuvant therapy and surgery

Neoadjuvant Therapy in Resectable Disease However, 15% of the patients developed into unresectable disease because of disease progression J Clin Oncol Jul 20;26(21): doi: /JCO Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA.

Potential Disadvantages of Neoadjuvant Therapy Requirement for biliary decompression before chemotherapy Potential complications from biliary stents Requirement for tissue diagnosis before chemotherapy Procedure related Cx including seeding of tumor cells Percutaneous FNA causing 16.3% peritoneal seeding Side effects from chemotherapy Gastrointest Endosc Nov;58(5): Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Micames C, Jowell PS, White R, Paulson E, Nelson R, Morse M, Hurwitz H, Pappas T, Tyler D, McGrath K.

Conclusion of Neoadjuvant Therapy on Resectable Pancreatic Cancer The adoption is still controversial Improvement of survival but risk of disease progression at the same time No global consensus is reached at the moment National Comprehensive Cancer Network (NCCN): Does not recommend Except on clinical trial

Potential benefit of neoadjuvant therapy in borderline resectable disease The administration is not affected by the surgical morbidities 20% of patients did not receive the assigned adjuvant therapy Occult metastases are allowed to manifest exclude patient from resection avoid the surgical morbidity Improve the chance of negative resection margin Increase the chance of resection Ann Surg 1999; 230:776–82. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.

Neoadjuvant therapy in borderline resectable disease Several trials have revealed that neoadjuvant treatment is effective in borderline resectable case

Recent retrospective study on borderline resectable disease 61.7% negative margin of resection with neoadjuvant chemoradiation 38.3% negative margin of resection without neoadjuvant chemoradiation J Clin Oncol 30, 2012 (suppl 4; abstr 304) Margin status and neoadjuvant chemoradiation in patients with borderline resectable pancreatic cancer Pavlos Papavasiliou, Jonathan R Piposar, Rodrigo Arrangoiz, Kathryn T Chen, Fang Zhu, Yun Shin Chun, John Parker Hoffman Neoadjuvant therapy in borderline resectable disease

Respective review on patients with pancreatic cancer resection Patients with borderline resectable cancer received neoadjuvant therapy 46% underwent surgical resection 67% had margin-negative (R0) resection Neoadjuvant therapy in borderline resectable disease

Median survival: 23.3 months Similar to resectable disease HPB (Oxford) Feb;12(1):73-9. doi: /j x. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA. Neoadjuvant therapy in borderline resectable disease

No randomized phase III trials for comparison Although there is no high level evidence supporting its use Neoadjuvant therapy is still an option Improve treatment outcome Neoadjuvant therapy in borderline resectable disease

Neoadjuvant Regimen There is no standard regimen at the moment In early days Radiotherapy Progress to switch to chemoradiation EBRT + 5-FU Recently Gemcitabine-based chemoradiation

Conclusion Pancreatic cancer is an aggressive malignancy with minority of the patients suitable for surgical resection Adjuvant therapy can improve the outcome of the illness The role of neoadjuvant therapy is still under further exploration

Conclusion Resectable case Suggest proceeding to surgery ASAP Except in clinical trial Borderline resectable case Neoadjuvant therapy is an option

Reference J Gastrointest Surg Mar-Apr;5(2): Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL. Arch Surg Aug;120(8): Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Kalser MH, Ellenberg SS. J Clin Oncol26: 2008 Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotheraoy with gemcitabine versus observation in patients with resected pancreatic cancer. Neuhaus P, Riess H, etal. Ann Surg 1999; 230:776–82. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Ann Surg Oncol Mar;8(2): Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB. J Clin Oncol Jul 20;26(21): doi: /JCO Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Gastrointest Endosc Nov;58(5): Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Micames C, Jowell PS, White R, Paulson E, Nelson R, Morse M, Hurwitz H, Pappas T, Tyler D, McGrath K. J Clin Oncol 30, 2012 (suppl 4; abstr 304) Margin status and neoadjuvant chemoradiation in patients with borderline resectable pancreatic cancer Pavlos Papavasiliou, Jonathan R Piposar, Rodrigo Arrangoiz, Kathryn T Chen, Fang Zhu, Yun Shin Chun, John Parker Hoffman HPB (Oxford) Feb;12(1):73-9. doi: /j x. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA.

THANK YOU!